研究领域

Pharmacy and Experimental Pharmacology

Prof. Stephen Ackland is Staff Specialist, Department of Medical Oncology, Calvary Mater Newcastle Hospital and Professor, Faculty of Health, University of Newcastle. He is the Director, Hunter Cancer Research Alliance; Director, University of Newcastle Priority Research Centre for Cancer Research Innovation and Translation; Director of Clinical Cancer Research Network HNE Health; Co-director of Hunter Medical Research Institute Cancer Research Program. He has played a key role in organisation, harmonisation and enhancements of translational and clinical research locally, on a state basis and nationally. He is Editor-in-Chief, Asia-Pacific Journal of Clinical Oncology. He is an inaugural member of the PRIMe consortium (Pharmacogenomics Research towards Individualised Medicine), a NSW Cancer Council-funded collaboration of 8 NSW hospitals and research institutes with the aim of facilitating cancer pharmacogenomics research in NSW.

近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

2016 Khasraw M, Lee A, McCowatt S, Kerestes Z, Buyse ME, Back M, et al., 'Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial', JOURNAL OF NEURO-ONCOLOGY, 128 163-171 (2016) 2016 Folprecht G, Pericay C, Saunders MP, Thomas A, Lopez Lopez R, Roh JK, et al., 'Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: The AFFIRM study', Annals of Oncology, 27 1273-1279 (2016) [C1] 2016 McLachlan SA, Fisher RJ, Zalcberg J, Solomon M, Burmeister B, Goldstein D, et al., 'The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04)', European Journal of Cancer, 55 15-26 (2016) [C1] 2016 Fradgley EA, Paul CL, Bryant J, Collins N, Ackland SP, Bellamy D, Levi CR, 'Collaborative Patient-Centered Quality Improvement: A Cross-Sectional Survey Comparing the Types and Numbers of Quality Initiatives Selected by Patients and Health Professionals.', Eval Health Prof, (2016) 2016 Guo ST, Chi MN, Yang RH, Guo XY, Zan LK, Wang CY, et al., 'INPP4B is an oncogenic regulator in human colon cancer.', Oncogene, 35 3049-3061 (2016) 2015 Bryant J, Sanson-Fisher R, Fradgley E, Regan T, Hobden B, Ackland SP, 'Oncology patients overwhelmingly support tissue banking.', BMC Cancer, 15 413 (2015) [C1] 2014 Yip D, Zalcberg J, Ackland S, Barbour AP, Desai J, Fox S, et al., 'Controversies in the management of gastrointestinal stromal tumors', Asia-Pacific Journal of Clinical Oncology, 10 216-227 (2014) [C1] 2013 Ackland S, Goldstein D, McJannett M, 'Forty years of COSA - Contributions to oncology teaching and research', Cancer Forum, 37 238-242 (2013) [C2] 2013 Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, et al., 'Current opinion on optimal treatment for colorectal cancer', EXPERT REVIEW OF ANTICANCER THERAPY, 13 597-611 (2013) [C1] 2013 Ackland S, Fukuda Y, '2012: Year in Review - from dragons to snakes', Asia-Pacific Journal of Clinical Oncology, 9 1-1 (2013) [C3] 2012 Goldstein D, Spry N, Cummins MM, Brown C, Van Hazel GA, Carroll S, et al., 'The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer', British Journal of Cancer, 106 61-69 (2012) [C1] 2012 Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al., 'Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04', Journal of Clinical Oncology, 30 3827-3833 (2012) [C1] 2012 Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, et al., 'Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C', ANNALS OF ONCOLOGY, 23 1531-1536 (2012) [C1] 2012 Zdenkowski N, Chen S, Van Der Westhuizen A, Ackland S, 'Curative strategies for liver metastases from colorectal cancer: A review', Oncologist, 17 201-211 (2012) [C1] 2012 Garg MB, Lincz L, Adler K, Scorgie FE, Ackland S, Sakoff JA, 'Predicting 5-Fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length - A multivariate analysis', British Journal of Cancer, 107 1525-1533 (2012) [C1] 2012 Ackland S, Fukuda Y, '2011: Year in review - From rabbits to dragons', Asia-Pacific Journal of Clinical Oncology, 8 1-2 (2012) [C3] 2011 Garg MB, Sakoff JA, Ackland S, 'A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 879 2201-2205 (2011) [C1] 2011 Lee CK, Hudson M, Stockler M, Coates AS, Ackland S, Gebski V, et al., 'A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer', Breast Cancer Research and Treatment, 129 467-476 (2011) [C1] 2011 Ackland S, Fukuda Y, '2011: Year in Review - from rabbits to dragons', Asia-Pacific Journal of Clinical Oncology, 8 1-2 (2011) 2011 Ackland S, 'Cancer in Australia: A model for other Asia-Pacific countries', Asia-Pacific Journal of Clinical Oncology, 7 323-324 (2011) [C3]